Astley-Sparke Philip 4

What Happened
Philip Astley‑Sparke, a director of Replimune Group, received equity awards on April 1, 2026. The filing reports two grants: 50,000 restricted stock units (RSUs) and 75,000 derivative awards (stock option-type award), both issued at $0.00 per share (no cash paid).

Key Details

• Transaction date: 2026-04-01. Both entries are coded "A" (award/grant).
• Consideration: $0.00 per share; total cash value reported = $0 (these are compensation awards, not open‑market purchases).
• Vesting / terms:
  • RSUs (50,000): each RSU converts to one share; 25% vest on May 15, 2027, remainder vests in three roughly equal annual installments through May 15, 2030. (Footnote F1)
  • Derivative award (75,000): 25% of the shares vest on April 1, 2027; remaining shares vest in ~36 equal monthly installments thereafter. (Footnote F2)
• Shares owned after transaction: not specified in this Form 4.
• Filing timeliness: This Form 4 was filed late due to an inadvertent administrative error (timeliness flag: L). Late filing delays public disclosure of insider activity and reduces near‑term transparency.

Context

• These are compensation grants to a director (not open‑market purchases or sales). Awards at $0 typically reflect standard equity compensation and do not necessarily signal an immediate bullish or bearish trading intent.
• The derivative entry appears to be a time‑vested option‑style award; no exercise or immediate sale was reported.